Target type: biologicalprocess
The cascade of processes by which a signal interacts with a receptor, causing a change in the level or activity of a second messenger or other downstream target, and ultimately leading to the activation, perpetuation, or inhibition of an immune response. [GOC:add, ISBN:0781735149, PMID:15771571]
The immune response-regulating signaling pathway is a complex and intricate network of molecular interactions that orchestrates the body's defense against pathogens and other harmful invaders. It involves a coordinated interplay of various cells, soluble mediators, and signaling molecules, ensuring an appropriate and balanced immune response. The pathway can be broadly divided into three main phases:
1. **Recognition of the Pathogen:**
* **Innate Immune Response:** The first line of defense involves innate immune cells such as macrophages, neutrophils, and natural killer (NK) cells. These cells express pattern recognition receptors (PRRs) that detect pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS) on bacteria or viral double-stranded RNA. Upon recognition, these cells initiate a rapid response by releasing pro-inflammatory cytokines, such as TNF-alpha, IL-1beta, and IL-6.
* **Adaptive Immune Response:** In addition to innate immunity, the adaptive immune response involves highly specific recognition of antigens, which are unique molecules present on pathogens. This recognition is mediated by lymphocytes, specifically T cells and B cells.
* **Antigen Presentation:** Antigen-presenting cells (APCs), such as dendritic cells and macrophages, capture antigens and present them to T cells. These APCs express MHC molecules, which display the antigen fragments to T cell receptors (TCRs).
2. **Signal Transduction and Activation:**
* **Cytokine Signaling:** The recognition of PAMPs or antigens triggers a cascade of intracellular signaling events, leading to the activation of various transcription factors and the production of cytokines. These cytokines amplify the immune response and coordinate the activities of different immune cells.
* **T Cell Receptor Signaling:** The interaction between the TCR and MHC-antigen complex initiates a signaling cascade within T cells. This cascade involves various kinases and adaptor proteins, ultimately leading to the activation of transcription factors such as NF-κB and AP-1.
* **B Cell Receptor Signaling:** Similar to T cells, B cells also have receptors that recognize antigens. Upon antigen binding, B cells undergo activation and differentiation into antibody-secreting plasma cells.
3. **Effector Response:**
* **T Cell-Mediated Immunity:** Activated T cells differentiate into different effector subtypes, such as cytotoxic T lymphocytes (CTLs) and helper T cells. CTLs directly kill infected cells, while helper T cells support other immune cells by secreting cytokines.
* **Humoral Immunity:** B cells produce antibodies that bind to antigens, neutralizing pathogens and facilitating their clearance by other immune cells.
* **Immune Memory:** The adaptive immune response generates memory cells that persist in the body and can quickly respond to subsequent encounters with the same pathogen, ensuring long-lasting immunity.
The immune response-regulating signaling pathway is a highly dynamic and adaptable system that ensures appropriate immune responses to a wide range of threats. It is tightly regulated to prevent excessive inflammation and autoimmune reactions, while maintaining a robust defense against pathogens. Disruptions in this intricate network can lead to various immune dysfunctions, such as allergies, autoimmune diseases, and immunodeficiency.
'"
Protein | Definition | Taxonomy |
---|---|---|
Platelet glycoprotein VI | A platelet glycoprotein VI that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9HCN6] | Homo sapiens (human) |
Pro-cathepsin H | A cathepsin H that is encoded in the genome of human. [PRO:DNx, UniProtKB:P09668] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
gamma-aminobutyric acid | gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4. gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system. | amino acid zwitterion; gamma-amino acid; monocarboxylic acid | human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule |
losartan | losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II. | biphenylyltetrazole; imidazoles | angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist |
valsartan | valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity. Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION. | biphenylyltetrazole; monocarboxylic acid; monocarboxylic acid amide | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic |
biphenyl-2-carboxylic acid | biphenyl-2-carboxylic acid: structure in first source | ||
honokiol | biphenyls | ||
leupeptin | aldehyde; tripeptide | bacterial metabolite; calpain inhibitor; cathepsin B inhibitor; EC 3.4.21.4 (trypsin) inhibitor; serine protease inhibitor | |
e 64 | E 64: cysteine protease inhibitor of microbial origin, which inhibits cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.-) | dicarboxylic acid monoamide; epoxy monocarboxylic acid; guanidines; L-leucine derivative; zwitterion | antimalarial; antiparasitic agent; protease inhibitor |
olmesartan | olmesartan: an active metabolite of CS 866 | biphenylyltetrazole | angiotensin receptor antagonist; antihypertensive agent |
cinanserin | cinanserin : An aryl sulfide that is (2E)-3-phenyl-N-(2-sulfanylphenyl)prop-2-enamide in which the hydrogen of the thiol group is substituted by a 3-(dimethylamino)propyl group. It is a 5-hydroxytryptamine receptor antagonist and an inhibitor of SARS-CoV replication. Cinanserin: A serotonin antagonist with limited antihistaminic, anticholinergic, and immunosuppressive activity. | aryl sulfide; cinnamamides; secondary carboxamide; tertiary amino compound | anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor |
pepstatin | pepstatin: inhibits the aspartic protease endothiapepsin | pentapeptide; secondary carboxamide | bacterial metabolite; EC 3.4.23.* (aspartic endopeptidase) inhibitor |
exp-3179 | |||
ca 074 | |||
odanacatib | odanacatib: a selective inhibitor of cathepsin K for the treatment of post-menopausal osteoporosis; structure in first source | ||
glaucocalyxin a | glaucocalyxin A: chemical constituent of Rabdosia japonica var. glaucocalyx | ||
calpain inhibitor iii | calpain inhibitor III: potential anticataract drug | ||
pci 32765 | ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies. ibrutinib: a Btk protein inhibitor | acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide | antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor |
gallinamide a | gallinamide A: antimalarial peptide from marine cyanobacteria | ||
6-(3,5-difluoroanilino)-9-ethyl-2-purinecarbonitrile | 6-aminopurines | ||
9-(3,5-difluorophenyl)-6-(ethylamino)-2-purinecarbonitrile | imidazoles | ||
grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source | ||
acp-196 | acalabrutinib : A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. acalabrutinib: inhibits Bruton’s tyrosine kinase; has antineoplastic activity | aromatic amine; benzamides; imidazopyrazine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; ynone | antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor |